Logo

OSRH

OSR Holdings, Inc.

OSRH

OSR Holdings, Inc. • NASDAQ
$0.75 ▲ 9.79% (+0.07)
Market Cap $19.10 M
52w High $12.54
52w Low $0.45
Dividend Yield 0%
P/E -2.66
Volume 1.24M
Outstanding Shares 25.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $627.747K ▼ $4.065M ▼ $-3.195M ▼ -508.943% ▼ $-0.1 ▼ $-2.059M ▲
Q2-2025 $1.136M ▲ $5.262M ▲ $331.414K ▲ 29.186% ▲ $0.02 ▲ $-2.837M ▲
Q1-2025 $761.272K ▲ $3.087M ▲ $-11.393M ▼ -1.497K% ▼ $-1.04 ▼ $-9.103M ▼
Q4-2024 $-2.395M ▼ $2.144M ▼ $-2.022M ▲ 84.423% ▲ $0.47 ▲ $-1.907M ▼
Q3-2024 $849.802K $3.865M $-3.462M -407.342% $-0.057 $-757.154K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.177M ▲ $177.29M ▼ $43.132M ▼ $81.945M ▼
Q2-2025 $1.584M ▼ $185.415M ▲ $46.262M ▲ $83.702M ▲
Q1-2025 $1.596M ▲ $174.55M ▲ $42.268M ▲ $75.76M ▲
Q4-2024 $66.135K ▲ $2.303M ▼ $8.789M ▲ $-6.486M ▼
Q3-2024 $12.236K $20.926M $6.011M $14.915M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.127M ▼ $-2.711M ▼ $-726.632K ▼ $4.116M ▲ $592.903K ▲ $0 ▲
Q2-2025 $331.414K ▲ $-482.607K ▼ $-528.424K ▼ $891.482K ▲ $-11.291K ▼ $-485.29K ▼
Q1-2025 $-11.393M ▼ $-64.069K ▲ $1.186M ▼ $149.381K ▲ $1.254M ▲ $-64.069K ▲
Q4-2024 $-2.022M ▼ $-502.905K ▼ $18.973M ▲ $-18.416M ▼ $53.899K ▲ $-502.909K ▼
Q3-2024 $-230.961K $-226.88K $-150K $270K $-106.88K $-226.88K

Five-Year Company Overview

Income Statement

Income Statement OSR Holdings looks like a classic early‑stage biotech: it has essentially no recurring revenue yet and is living in a pre‑commercial phase. Reported profit and loss figures move around, but that’s mostly noise on a very small base rather than evidence of a stable earnings engine. The key point: the business model today is about funding research and trials, not about selling products. That means near‑term performance will be driven more by R&D and deal activity than by traditional sales and margins, and losses are to be expected until at least one program reaches market or is out‑licensed on meaningful terms.

Balance Sheet

Balance Sheet The balance sheet is small and fragile, with limited assets and a history of using debt and equity to finance operations. Recent figures suggest that obligations may now slightly exceed recorded assets, which is a sign of financial strain rather than balance sheet strength. For a holding company in biotech, this isn’t unusual, but it does underline dependence on external funding, partnerships, and successful capital raises. The room for error is relatively thin: clinical setbacks or a difficult funding environment could quickly become a balance sheet problem.

Cash Flow

Cash Flow Reported cash flow data are essentially flat, which in practice usually means the numbers are not very informative rather than that the company is truly cash‑neutral. In reality, an early‑stage biotech with multiple programs almost certainly has ongoing cash burn from research, trials, and corporate costs. The business therefore likely relies on a mix of financing, milestone payments, and potential licensing or asset deals to keep funding operations. The key risk is the classic one for young biotechs: access to fresh capital and the timing of any partnership cash flows.

Competitive Edge

Competitive Edge OSR’s competitive position rests on having several differentiated platforms rather than on scale or current market share. It is trying to carve out niches in oral cancer immunotherapy, regenerative biologics, and non‑invasive glucose monitoring—each of which, if successful, could be meaningfully disruptive in its own space. The company benefits from diversification across three distinct healthcare areas and from the validation implied by external collaborations and accelerator programs. However, it competes, directly or indirectly, against much larger pharma and device companies with deeper pockets and established commercial footprints. Its moat is therefore more about novelty and first‑mover potential than about brand, size, or distribution. Overall, OSR looks competitively interesting but still very much in the “prove it” phase: strong ideas and platforms, but limited current market presence and heavy execution risk.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of OSR. Through Vaximm, it is pushing an oral cancer immunotherapy approach that could offer much easier treatment than injectable options if clinical data continue to support it. Through Darnatein, it is working on biologics intended to actually repair damaged tissue in degenerative diseases, which is more ambitious than typical symptom control. And via Woori IO, it is moving into non‑invasive glucose monitoring, aiming for needle‑free, wearable‑friendly diabetes management. These areas target very large, growing markets and tap into powerful trends: patient convenience, disease‑modifying treatments, and integration with consumer technology. The flip side is that most of these programs are still in trials or preclinical stages, so timelines are long, regulatory risk is high, and the outcome for any specific asset is uncertain. R&D intensity and capital needs are likely to stay high for years.

Summary

OSR Holdings is an early‑stage, innovation‑driven healthcare holding company with very limited current revenues and a thin, somewhat stressed balance sheet, which is typical for young biotechs but still an important risk factor. The business today is essentially a portfolio of scientific and clinical bets, not a mature operating company. On the positive side, the company is positioned in three highly attractive areas—cancer immunotherapy, regenerative medicine, and non‑invasive glucose monitoring—each with clear medical needs and large potential markets. Its strategy of using subsidiaries and partnerships to advance multiple platforms gives it diversification and some external validation. The main uncertainties revolve around clinical trial outcomes, regulatory approvals, execution on partnerships and acquisitions, and ongoing access to funding. If even one of its lead programs progresses successfully, the profile of the company could change significantly; if not, the combination of scientific and financial risk could become more pressing. Overall, OSR is best understood as a high‑risk, high‑uncertainty, research‑driven story rather than a traditional earnings‑focused healthcare business at this stage.

NEWS

November 21, 2025 · 9:20 AM UTC

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Read more

November 14, 2025 · 11:10 AM UTC

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

Read more

November 6, 2025 · 8:30 AM UTC

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Read more

October 20, 2025 · 11:39 AM UTC

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Read more

October 14, 2025 · 8:30 AM UTC

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

Read more